Skip to main content

Terns Pharmaceuticals Inc (TERN) Stock

Terns Pharmaceuticals Inc Stock Details, Movements and Public Alerts

Stock Details

Terns Pharmaceuticals Inc (TERN), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $46.07. Over the past 52 weeks, it has ranged between $1.87 and $48.26. This places the current price at 95.5% of its 52-week high and 2370.2% above its 52-week low. Recent trading volume was recorded at 2,194,793. The 14-day Relative Strength Index (RSI) stands at 66.35, suggesting neutral conditions. The stock is currently trading above its 50-day moving average of $38.37 by 20.07%. Similarly, it is above its 200-day moving average of $17.34 by 165.69%. The MACD histogram is 0.35, indicating bullish momentum (MACD Line: 1.32, Signal Line: 0.97).

52-Week Range

$48.26 - $1.87

-4.54% from high · +2370.24% from low

Avg Daily Volume

2,043,539

20-day average

100-day avg: 3,265,795

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

17.81

EV/EBITDA

-5.80

EPS (TTM)

-$1.02

Price to Sales

302.64

Beta

-0.29

Less volatile than market

Q:How is TERN valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is TERN's risk profile compared to the market?
With a beta of -0.29, Terns Pharmaceuticals Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 17.81 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

EBITDA

$-108,331,000

Return on Equity

-29.10%

Return on Assets

-19.90%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is TERN's business model?
Profitability metrics are not available for this stock.
Q:What are TERN's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$5.1B

Revenue (TTM)

$1.00M

Revenue/Share (TTM)

$0.04

Shares Outstanding

108.77M

Book Value/Share

$3.25

Asset Type

Common Stock

Q:What is TERN's market capitalization and position?
Terns Pharmaceuticals Inc has a market capitalization of $5.1B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 108.77M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does TERN's price compare to its book value?
Terns Pharmaceuticals Inc's book value per share is $3.25, while the current stock price is $46.07, resulting in a price-to-book (P/B) ratio of 14.19. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$58.11

26.13% upside potential

Analyst Recommendations

Strong Buy

2

Buy

9

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for TERN?
11 analysts cover TERN with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $58.11 implies 26.1% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on TERN?
Current analyst recommendations:2 Strong Buy, 9 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 15, 2026, 02:21 AM

Technical Indicators

RSI (14-day)

66.35

Neutral

50-Day Moving Average

$38.37

20.07% above MA-50

200-Day Moving Average

$17.34

165.69% above MA-200

MACD Line

1.32

MACD Signal

0.97

MACD Histogram

0.35

Bullish

Q:What does TERN's RSI value tell investors?
The RSI (Relative Strength Index) for TERN is currently 66.35, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
Q:How should traders interpret TERN's MACD and moving average crossovers?
MACD analysis shows the MACD line at 1.32 above the signal line at 0.97, with histogram at 0.35. This bullish crossover suggests upward momentum is building. The 50-day MA ($38.37) is above the 200-day MA ($17.34), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Mar 1, 2026, 12:31 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for TERN and get notified when the price changes.

Stay Ahead of the Market with Terns Pharmaceuticals Inc Alerts

Set up price alerts for Terns Pharmaceuticals Inc and get notified instantly when the price hits your target. Never miss an important price movement again.